

Quarter 1 - January 2020 Corrected Records

Q1 2020 Change Log		Corrected Records			121 Corrections
Quarter	Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per Unit Dose	
Q4 2019	ALCOHOL	TOPICAL	GEL	96.94 %w/w	
Q1 2020	ALCOHOL	TOPICAL	GEL	64.38 %w/v	
Q4 2019	AMMONIA SOLUTION	ORAL	CAPSULE	0.03 mg	
Q1 2020	AMMONIA SOLUTION	ORAL	CAPSULE	0.02 mg/mg	
Q4 2019	AMMONIA SOLUTION	ORAL	CAPSULE, EXTENDED RELEASE	0.01 mg/mg	
Q1 2020	AMMONIA SOLUTION	ORAL	CAPSULE, EXTENDED RELEASE	NA	
Q4 2019	BUTYLATED HYDROXYANISOLE	ORAL	TABLET, ORALLY DISINTEGRATING	0.60 mg	
Q1 2020	BUTYLATED HYDROXYANISOLE	ORAL	TABLET, ORALLY DISINTEGRATING	0.42 mg	
Q4 2019	BUTYLATED HYDROXYTOLUENE	ORAL	TABLET, ORALLY DISINTEGRATING	0.30 mg	
Q1 2020	BUTYLATED HYDROXYTOLUENE	ORAL	TABLET, ORALLY DISINTEGRATING	0.21 mg	
Q4 2019	CARBOMER 1382	TOPICAL	GEL, METERED	0.90 %w/w	
Q1 2020	CARBOMER COPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)	TOPICAL	GEL, METERED	0.90 %w/w	
Q4 2019	CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)	TOPICAL	GEL	3.50 %w/w	
Q1 2020	CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)	TOPICAL	GEL	0.88 %w/v	
Q4 2019	CARBOXYPOLYMETHYLENE	ORAL	TABLET, EXTENDED RELEASE	195.00 mg	
Q1 2020	CARBOMER HOMOPOLYMER	ORAL	TABLET, EXTENDED RELEASE	195.00 mg	
Q4 2019	CARBOXYPOLYMETHYLENE	RECTAL	ENEMA	NA	
Q1 2020	CARBOMER HOMOPOLYMER	RECTAL	ENEMA	NA	
Q4 2019	CARBOXYPOLYMETHYLENE	TOPICAL	DISC	NA	
Q1 2020	CARBOMER HOMOPOLYMER	TOPICAL	DISC	NA	
Q4 2019	CARBOXYPOLYMETHYLENE	TOPICAL	GEL	0.70 %w/w	
Q1 2020	CARBOMER HOMOPOLYMER	TOPICAL	GEL	0.70 %w/w	
Q4 2019	CARBOXYPOLYMETHYLENE	TOPICAL	LOTION	0.53 %w/w	
Q1 2020	CARBOMER HOMOPOLYMER	TOPICAL	LOTION	0.53 %w/w	
Q4 2019	CARBOXYPOLYMETHYLENE	TOPICAL	PATCH	0.10 mg/mg	
Q1 2020	CARBOMER HOMOPOLYMER	TOPICAL	PATCH	0.10 mg/mg	
Q4 2019	CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM	ORAL	TABLET	200.00 mg	
Q1 2020	CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM	ORAL	TABLET	160.00 mg	
Q4 2019	CITRIC ACID MONOHYDRATE	INTRAVENOUS	INJECTION	8.27 %w/v	
Q1 2020	CITRIC ACID MONOHYDRATE	INTRAVENOUS	INJECTION	3.85 %w/v	
Q4 2019	COCO DIETHANOLAMIDE	TOPICAL	SOLUTION	4.00 %w/w	
Q1 2020	COCO DIETHANOLAMIDE	TOPICAL	SOLUTION	2.50 %w/v	
Q4 2019	ETHYLCELLULOSE	ORAL	CAPSULE	69.97 mg	
Q1 2020	ETHYLCELLULOSE	ORAL	CAPSULE	32.20 mg	
Q4 2019	ETHYLCELLULOSE	ORAL	CAPSULE, EXTENDED RELEASE	144.00 mg	
Q1 2020	ETHYLCELLULOSE	ORAL	CAPSULE, EXTENDED RELEASE	134.25 mg	
Q4 2019	ETHYLCELLULOSE	ORAL	GRANULE, FOR SUSPENSION	85.00 mg/ 5.00 ml	
Q1 2020	ETHYLCELLULOSE	ORAL	GRANULE, FOR SUSPENSION	10.62 mg/ 5.00 ml	
Q4 2019	ETHYLCELLULOSE	ORAL	TABLET	291.50 mg	
Q1 2020	ETHYLCELLULOSE	ORAL	TABLET	120.80 mg	
Q4 2019	ETHYLCELLULOSE	ORAL	TABLET, EXTENDED RELEASE	308.80 mg	
Q1 2020	ETHYLCELLULOSE	ORAL	TABLET, EXTENDED RELEASE	300.00 mg	
Q4 2019	ETHYLCELLULOSE	ORAL	CAPSULE, COATED	18 mg	
Q1 2020	ETHYLCELLULOSE AQUEOUS DISPERSION	ORAL	CAPSULE, COATED	18 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	CAPSULE	93.60 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	CAPSULE	93.60 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	CAPSULE, COATED	18.81 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	CAPSULE, COATED	18.81 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	CAPSULE, COATED PELLETS	3.94 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	CAPSULE, COATED PELLETS	3.94 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	CAPSULE, DELAYED RELEASE	150.00 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	CAPSULE, DELAYED RELEASE	150.00 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	CAPSULE, EXTENDED RELEASE	100.69 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	CAPSULE, EXTENDED RELEASE	100.69 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	GRANULE, FOR SUSPENSION	NA	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	GRANULE, FOR SUSPENSION	13.70 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	TABLET	91.00 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	TABLET	91.00 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	TABLET, COATED PARTICLES	27.90 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	TABLET, COATED PARTICLES	27.90 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	TABLET, DELAYED RELEASE	140.00 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	TABLET, DELAYED RELEASE	140.00 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	15.00 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	15.00 mg	
Q4 2019	EUDRAGIT L 30 D	ORAL	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	95.00 mg	
Q1 2020	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A	ORAL	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	95.00 mg	
Q4 2019	FD&C RED NO. 40--ALUMINUM LAKE	ORAL	TABLET, FILM COATED	2.50 mg	
Q1 2020	FD&C RED NO. 40--ALUMINUM LAKE	ORAL	TABLET, FILM COATED	0.68 mg	
Q4 2019	GLYCERYL STEARATE/PEG STEARATE	ORAL	TABLET	1.80 mg	
Q1 2020	GLYCERYL STEARATE/PEG-100 STEARATE	ORAL	TABLET	1.80 mg	
Q4 2019	GLYCERYL STEARATE/PEG STEARATE	ORAL	TABLET, COATED	1.80 mg	
Q1 2020	GLYCERYL STEARATE/PEG-100 STEARATE	ORAL	TABLET, COATED	1.80 mg	
Q4 2019	GLYCERYL STEARATE/PEG STEARATE	RECTAL	SUPPOSITORY	36.00 mg	
Q1 2020	GLYCERYL STEARATE/PEG-100 STEARATE	RECTAL	SUPPOSITORY	36.00 mg	

Q4 2019	GLYCERYL STEARATE/PEG STEARATE	TOPICAL	CREAM	6.00 %w/w
Q1 2020	GLYCERYL STEARATE/PEG-100 STEARATE	TOPICAL	CREAM	7.5 %w/w
Q4 2019	HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	SYRUP	100.00 mg/ 5.00 ml
Q1 2020	HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	SYRUP	7.50 mg/ 5.00 ml
Q4 2019	HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	TABLET	12.00 mg
Q1 2020	HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	TABLET	NA
Q4 2019	HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, EXTENDED RELEASE	175.00 mg
Q1 2020	HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, EXTENDED RELEASE	20.00 mg
Q4 2019	HYDROXYETHYL CELLULOSE, UNSPECIFIED	OPHTHALMIC	SOLUTION	0.50 %w/v
Q1 2020	HYDROXYETHYL CELLULOSE, UNSPECIFIED	OPHTHALMIC	SOLUTION	0.35 %w/w
Q4 2019	HYDROXYPROPYL CELLULOSE	ORAL	CAPSULE	3.00 mg
Q1 2020	HYDROXYPROPYL CELLULOSE	ORAL	CAPSULE	1.75 mg
Q4 2019	HYDROXYPROPYL CELLULOSE	ORAL	CAPSULE, EXTENDED RELEASE	93.94 mg
Q1 2020	HYDROXYPROPYL CELLULOSE	ORAL	CAPSULE, EXTENDED RELEASE	42.42 mg
Q4 2019	HYDROXYPROPYL CELLULOSE	ORAL	TABLET	95.00 mg
Q1 2020	HYDROXYPROPYL CELLULOSE	ORAL	TABLET	93.84 mg
Q4 2019	HYDROXYPROPYL CELLULOSE	ORAL	TABLET, DELAYED RELEASE	10.00 mg
Q1 2020	HYDROXYPROPYL CELLULOSE	ORAL	TABLET, DELAYED RELEASE	0.55 mg
Q4 2019	HYDROXYPROPYL CELLULOSE	ORAL	TABLET, FILM COATED	24.00 mg
Q1 2020	HYDROXYPROPYL CELLULOSE	ORAL	TABLET, FILM COATED	15.00 mg
Q4 2019	HYPROMELLOSES	NASAL	SPRAY	1.02 mg/ 1.00 ml
Q1 2020	HYPROMELLOSE	NASAL	SPRAY	1.00 mg/ 1.00 ml
Q4 2019	HYPROMELLOSES	ORAL	CAPSULE, DELAYED RELEASE	110.00 mg
Q1 2020	HYPROMELLOSE	ORAL	CAPSULE, DELAYED RELEASE	96.00 mg
Q4 2019	HYPROMELLOSES	ORAL	POWDER, FOR SUSPENSION	75.00 mg/ 5.00 ml
Q1 2020	HYPROMELLOSE	ORAL	POWDER, FOR SUSPENSION	65.00 mg/ 5.00 ml
Q4 2019	HYPROMELLOSES	ORAL	SUSPENSION	325.00 mg/ 5.00 ml
Q1 2020	HYPROMELLOSE	ORAL	SUSPENSION	100.00 mg/ 5.00 ml
Q4 2019	HYPROMELLOSES	ORAL	SYRUP	180.00 mg/ 5.00 ml
Q1 2020	HYPROMELLOSE	ORAL	SYRUP	4.50 mg/ 1.00 ml
Q4 2019	HYPROMELLOSES	ORAL	TABLET	444.40 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET	323.28 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, CHEWABLE	22.00 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, CHEWABLE	10.00 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, COATED	245.00 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, COATED	35.39 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, DELAYED RELEASE	127.29 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, DELAYED RELEASE	52.14 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, EXTENDED RELEASE	405.00 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, EXTENDED RELEASE	401.00 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, FILM COATED	536.80 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, FILM COATED	194.02 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	300.00 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	239.13 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, FOR SUSPENSION	45.00 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, FOR SUSPENSION	19.00 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, MULTILAYER, EXTENDED RELEASE	125.50 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, MULTILAYER, EXTENDED RELEASE	8.40 mg
Q4 2019	HYPROMELLOSES	ORAL	TABLET, ORALLY DISINTEGRATING	18.00 mg
Q1 2020	HYPROMELLOSE	ORAL	TABLET, ORALLY DISINTEGRATING	7.73 mg
Q4 2019	ISOPROPYL MYRISTATE	TOPICAL	GEL	10.00 %w/w
Q1 2020	ISOPROPYL MYRISTATE	TOPICAL	GEL	0.88 %w/v
Q4 2019	LAURAMINE OXIDE	TOPICAL	SOLUTION	16.00 %w/w
Q1 2020	LAURAMINE OXIDE	TOPICAL	SOLUTION	3.50 %w/v
Q4 2019	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	TABLET	80.00 mg
Q1 2020	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	TABLET	46.00 mg
Q4 2019	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, FILM COATED	50.00 mg
Q1 2020	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, FILM COATED	40.00 mg
Q4 2019	OPADRY II YS-1-7006 CLEAR	ORAL	TABLET, EXTENDED RELEASE	15.77 mg
Q1 2020	OPADRY II YS-1-7006 CLEAR	ORAL	TABLET, EXTENDED RELEASE	13.00 mg
Q4 2019	PALMITOSTEARIC ACID	ORAL	TABLET	6.00 mg
Q1 2020	STEARIC ACID	ORAL	TABLET	72.00 mg
Q4 2019	PALMITOSTEARIC ACID	ORAL	CAPSULE	5.00 mg
Q1 2020	STEARIC ACID	ORAL	CAPSULE	52.00 mg
Q4 2019	POLYETHYLENE GLYCOL 400	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	1.80 mg
Q1 2020	POLYETHYLENE GLYCOL 400	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	1.28 mg
Q4 2019	POLYOXYETHYLENE - POLYOXYPROPYLENE 1800	OPHTHALMIC	SOLUTION	NA
Q1 2020	PEG/PPG-4/30 COPOLYMER	OPHTHALMIC	SOLUTION	NA
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	AURICULAR (OTIC)	SOLUTION	0.20 %w/w
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	AURICULAR (OTIC)	SOLUTION	0.20 %w/w
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	INTRA-ARTICULAR	INJECTION	0.30 %w/v
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	INTRA-ARTICULAR	INJECTION	0.30 %w/v
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	INTRAMUSCULAR	INJECTION	0.30 %w/v
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	INTRAMUSCULAR	INJECTION	0.30 %w/v
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	INTRAVENOUS	INJECTION	68.00 mg
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	INTRAVENOUS	INJECTION	68.00 mg
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	INTRAVENOUS	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	0.68 %w/v
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	INTRAVENOUS	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	0.68 %w/v
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	INTRAVENOUS	INJECTION, SOLUTION	1.36 %w/v
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	INTRAVENOUS	INJECTION, SOLUTION	1.36 %w/v
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	NASAL	SOLUTION	680.00 mg
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	NASAL	SOLUTION	680.00 mg
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	NASAL	SPRAY	0.10 mg/ 0.10 ml
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	NASAL	SPRAY	0.10 mg/ 0.10 ml
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	OPHTHALMIC	SOLUTION	0.20 %w/w
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	OPHTHALMIC	SOLUTION	0.20 %w/w

Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	OPHTHALMIC	SUSPENSION	0.44 %w/w
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	OPHTHALMIC	SUSPENSION	0.44 %w/w
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	ORAL	CAPSULE, COATED PELLETS	17.00 mg
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	ORAL	CAPSULE, COATED PELLETS	17.00 mg
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	ORAL	SOLUTION	25.00 mg/ 5.00 ml
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	ORAL	SOLUTION	25.00 mg/ 5.00 ml
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	ORAL	SUSPENSION	50.00 mg/ 5.00 ml
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	ORAL	SUSPENSION	50.00 mg/ 5.00 ml
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	ORAL	SYRUP	13.66 mg/ 5.00 ml
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	ORAL	SYRUP	13.66 mg/ 5.00 ml
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	ORAL	TABLET	25.00 mg
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	ORAL	TABLET	25.00 mg
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	ORAL	TABLET, EXTENDED RELEASE	4.00 mg
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	ORAL	TABLET, EXTENDED RELEASE	4.00 mg
Q4 2019	POTASSIUM PHOSPHATE, MONOBASIC	SUBCUTANEOUS	INJECTION	0.27 %w/v
Q1 2020	MONOBASIC POTASSIUM PHOSPHATE	SUBCUTANEOUS	INJECTION	0.27 %w/v
Q4 2019	POVIDONE K90	TRANSDERMAL	SOLUTION	2.50 %w/w
Q1 2020	POVIDONE K90	TRANSDERMAL	SOLUTION	2.00 %w/v
Q4 2019	POVIDONES	INTRAVENOUS	INJECTION	20.00 mg
Q1 2020	POVIDONE	INTRAVENOUS	INJECTION	1.00 %w/v
Q4 2019	POVIDONES	OPHTHALMIC	SOLUTION	15.00 %w/v
Q1 2020	POVIDONE	OPHTHALMIC	SOLUTION	2.00 %w/v
Q4 2019	POVIDONES	OPHTHALMIC	SUSPENSION/ DROPS	1.50 %w/v
Q1 2020	POVIDONE	OPHTHALMIC	SUSPENSION/ DROPS	0.60 %w/v
Q4 2019	POVIDONES	ORAL	CAPSULE	130.00 mg
Q1 2020	POVIDONE	ORAL	CAPSULE	54.81 mg
Q4 2019	POVIDONES	ORAL	CAPSULE, DELAYED RELEASE	8.70 mg
Q1 2020	POVIDONE	ORAL	CAPSULE, DELAYED RELEASE	8.40 mg
Q4 2019	POVIDONES	ORAL	CAPSULE, EXTENDED RELEASE	102.73 mg
Q1 2020	POVIDONE	ORAL	CAPSULE, EXTENDED RELEASE	72.00 mg
Q4 2019	POVIDONES	ORAL	POWDER, FOR SOLUTION	5.00 mg
Q1 2020	POVIDONE	ORAL	POWDER, FOR SOLUTION	4.50 mg
Q4 2019	POVIDONES	ORAL	SUSPENSION, EXTENDED RELEASE	5.21 mg/ 5.00 ml
Q1 2020	POVIDONE	ORAL	SUSPENSION, EXTENDED RELEASE	0.61 mg/ 1.00 ml
Q4 2019	POVIDONES	ORAL	TABLET, CHEWABLE	21.00 mg
Q1 2020	POVIDONE	ORAL	TABLET, CHEWABLE	18.00 mg
Q4 2019	POVIDONES	ORAL	TABLET, DELAYED RELEASE	73.70 mg
Q1 2020	POVIDONE	ORAL	TABLET, DELAYED RELEASE	40.00 mg
Q4 2019	POVIDONES	ORAL	TABLET, EXTENDED RELEASE	219.03 mg
Q1 2020	POVIDONE	ORAL	TABLET, EXTENDED RELEASE	101.33 mg
Q4 2019	POVIDONES	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	53.33 mg
Q1 2020	POVIDONE	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	37.50 mg
Q4 2019	POVIDONES	ORAL	TABLET, ORALLY DISINTEGRATING	15.03 mg
Q1 2020	POVIDONE	ORAL	TABLET, ORALLY DISINTEGRATING	15.00 mg
Q4 2019	POVIDONES	ORAL	TROCHE	35.00 mg
Q1 2020	POVIDONE	ORAL	TROCHE	30.00 mg
Q4 2019	POVIDONES	SUBLINGUAL	TABLET	12.00 mg
Q1 2020	POVIDONE	SUBLINGUAL	TABLET	9.80 mg
Q4 2019	POVIDONES	TOPICAL	SOLUTION	4.00 %w/v
Q1 2020	POVIDONE	TOPICAL	SOLUTION	2.44 %w/w
Q4 2019	POVIDONES	TRANSDERMAL	FILM, EXTENDED RELEASE	16.00 mg
Q1 2020	POVIDONE	TRANSDERMAL	FILM, EXTENDED RELEASE	NA
Q4 2019	SODIUM BICARBONATE	INTRAMUSCULAR	INJECTION	13.50 %w/w
Q1 2020	SODIUM BICARBONATE	INTRAMUSCULAR	INJECTION	1.75 %w/v
Q4 2019	SODIUM CHLORIDE	INTRAOCULAR	SOLUTION	7.00 mg
Q1 2020	SODIUM CHLORIDE	INTRAOCULAR	SOLUTION	6.40 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	CAPSULE	11.10 mg
Q1 2020	ETHYLCELLULOSE DISPERSION TYPE B	ORAL	CAPSULE	11.10 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	CAPSULE, EXTENDED RELEASE	46.55 mg
Q1 2020	ETHYLCELLULOSE AQUEOUS DISPERSION	ORAL	CAPSULE, EXTENDED RELEASE	46.55 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	GRANULE	29.40 mg
Q1 2020	ETHYLCELLULOSE DISPERSION TYPE B	ORAL	GRANULE	29.40 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	TABLET	11.90 mg
Q1 2020	ETHYLCELLULOSE AQUEOUS DISPERSION	ORAL	TABLET	11.90 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	TABLET, DELAYED RELEASE	2.50 mg
Q1 2020	ETHYLCELLULOSE AQUEOUS DISPERSION	ORAL	TABLET, DELAYED RELEASE	2.50 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	CAPSULE, COATED PELLETS	39.80 mg
Q1 2020	ETHYLCELLULOSE DISPERSION TYPE B	ORAL	CAPSULE, COATED PELLETS	39.80 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	CAPSULE, DELAYED RELEASE	23.33 mg
Q1 2020	ETHYLCELLULOSE DISPERSION TYPE B	ORAL	CAPSULE, DELAYED RELEASE	23.33 mg
Q4 2019	SURELEASE E-719010 CLEAR	ORAL	TABLET, EXTENDED RELEASE	200 mg
Q1 2020	ETHYLCELLULOSE DISPERSION TYPE B	ORAL	TABLET, EXTENDED RELEASE	200 mg
Q4 2019	TALLOW GLYCERIDES	TOPICAL	AEROSOL	2.55 %w/w
Q1 2020	GLYCERYL PALMITOSTEARATE	TOPICAL	AEROSOL	2.55 %w/w
Q4 2019	TALLOW GLYCERIDES	TOPICAL	CREAM	2.78 %w/w
Q1 2020	GLYCERYL PALMITOSTEARATE	TOPICAL	CREAM	2.78 %w/w
Q4 2019	TALLOW GLYCERIDES	TOPICAL	EMULSION	2.55 %w/w
Q1 2020	GLYCERYL PALMITOSTEARATE	TOPICAL	EMULSION	2.55 %w/w
Q4 2019	VANILLA	ORAL	TABLET	0.80 mg
Q1 2020	VANILLA BEAN	ORAL	TABLET	0.80 mg
Q4 2019	VANILLA	ORAL	TABLET, ORALLY DISINTEGRATING	0.41 mg
Q1 2020	VANILLA BEAN	ORAL	TABLET, ORALLY DISINTEGRATING	0.41 mg

Quarter 1 - January 2020 Deleted Records

Q1 2020 Change Log	Deleted Records		64 Deletions
Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per Unit Dose
ACETIC ACID	OPHTHALMIC	POWDER, FOR SOLUTION	ADJ PH
ACETIC ACID	ORAL	INJECTION	ADJ PH
BENZALKONIUM CHLORIDE	INTRAOCULAR	SOLUTION	0.05 mg
CITRIC ACID MONOHYDRATE	INTRAOCULAR	SOLUTION	0.50 mg
CITRIC ACID MONOHYDRATE	INTRAVENOUS	POWDER FOR INJECTION DOSAGE FORM	ADJ PH
D&C YELLOW NO. 10-ALUMINUM LAKE	ORAL	CAPSULE, EXTENDED RELEASE	1.24 mg
D&C YELLOW NO. 10-ALUMINUM LAKE	ORAL	TABLET	2.00 mg
D&C YELLOW NO. 10-ALUMINUM LAKE	ORAL	TABLET, EXTENDED RELEASE	1.33 mg
D&C YELLOW NO. 10-ALUMINUM LAKE	ORAL	TABLET, FILM COATED	0.10 mg
D&C YELLOW NO. 10-ALUMINUM LAKE	TOPICAL	SOLUTION	NA
DOCUSATE SODIUM	ORAL	TABLET, FILM COATED, EXTENDED	0.03 mg
ETHYLCELLULOSE	ORAL	TABLET, CHEWABLE	8.80 mg
FLAVOR CHERRY 461566	ORAL	LOZENGE	60.00 mg
GLYCERYL STEARATE/PEG STEARATE	ORAL	TABLET	1.80 mg
GLYCERYL STEARATE/PEG STEARATE	ORAL	TABLET, COATED	1.80 mg
GLYCERYL STEARATE/PEG STEARATE	RECTAL	SUPPOSITORY	36.85 mg
GLYCERYL STEARATE/PEG STEARATE	TOPICAL	CREAM	6.00 %w/w
HYDROCHLORIC ACID	INTRAVENOUS	POWDER FOR INJECTION DOSAGE FORM	ADJ PH
HYDROXYETHYL CELLULOSE, UNSPECIFIED	AURICULAR (OTIC)	SUSPENSION	0.20 %w/w
HYDROXYETHYL CELLULOSE, UNSPECIFIED	BUCCAL	FILM	24.16 mg
HYDROXYETHYL CELLULOSE, UNSPECIFIED	OPHTHALMIC	SOLUTION/ DROPS	0.50 %w/v
HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	SOLUTION	25.00 mg/ 5.00 ml
HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	SUSPENSION	1.25 mg/ 1.00 ml
HYDROXYETHYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, FILM COATED, EXTENDED	99.75 mg
HYDROXYETHYL CELLULOSE, UNSPECIFIED	TOPICAL	GEL	1.50 %w/w
HYDROXYETHYL CELLULOSE, UNSPECIFIED	TOPICAL	LOTION	0.79 %w/w
HYDROXYETHYL CELLULOSE, UNSPECIFIED	TOPICAL	SOLUTION	0.60 %w/w
HYDROXYPROPYL BETADEX	ORAL	TABLET, ORALLY DISINTEGRATING	15.00 mg
HYDROXYPROPYL CELLULOSE	ORAL	TABLET, CHEWABLE	60.00 mg
HYPROMELLOSES	BUCCAL	TABLET	24.00 mg
HYPROMELLOSES	NASAL	POWDER	NA
HYPROMELLOSES	ORAL	GRANULE, FOR SUSPENSION	0.01 mg/mg
HYPROMELLOSES	ORAL	POWDER	45.59 mg
HYPROMELLOSES	ORAL	SUSPENSION/ DROPS	1.30 mg/ 1.00 ml
HYPROMELLOSES	RESPIRATORY (INHALATION)	POWDER	45.67 mg
HYPROMELLOSES	TOPICAL	SOLUTION/ DROPS	0.11 %w/v
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	CAPSULE	20.00 mg
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	CAPSULE, EXTENDED RELEASE	40.00 mg
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, CHEWABLE	25.00 mg
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, ORALLY DISINTEGRATING	33.60 mg
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED	ORAL	TABLET, ORALLY DISINTEGRATING,	40.00 mg
MICA	ORAL	TABLET	1.14 mg/mg
MICA	ORAL	TABLET, DELAYED RELEASE	1.42 mg
MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE)	ORAL	TABLET	0.50 mg/mg
MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE)	ORAL	TABLET, ORALLY DISINTEGRATING	0.04 mg
OPADRY YS-1-2115 YELLOW	ORAL	TABLET	14.14 mg
POLYVINYL ALCOHOL	INTRAOCULAR	SOLUTION	14.00 mg
POVIDONES	BUCCAL	TABLET, DELAYED RELEASE	0.50 mg
POVIDONES	INTRAVENOUS	INJECTION, POWDER, LYOPHILIZED,	20.00 mg
POVIDONES	OPHTHALMIC	SOLUTION/ DROPS	1.80 %w/v
POVIDONES	OPHTHALMIC	SUSPENSION	1.80 %w/w
POVIDONES	ORAL	GRANULE	201.63 mg
POVIDONES	ORAL	PELLET	3.00 mg
POVIDONES	ORAL	TABLET, CHEWABLE, EXTENDED	2.88 mg
POVIDONES	VAGINAL	INSERT	49.00 mg
PROSOLV SMCC 50	ORAL	TABLET, ORALLY DISINTEGRATING	119.60 mg
SODIUM CARBONATE	INTRAVENOUS	POWDER FOR INJECTION DOSAGE FORM	575.00 mg
SODIUM HYDROXIDE	INTRAMUSCULAR	POWDER FOR INJECTION DOSAGE FORM	ADJ PH
SODIUM HYDROXIDE	INTRAVENOUS	POWDER FOR INJECTION DOSAGE FORM	ADJ PH
SODIUM HYDROXIDE	RESPIRATORY (INHALATION)	INJECTION	ADJ PH
TALLOW GLYCERIDES	TOPICAL	AEROSOL	2.55 %w/w
TALLOW GLYCERIDES	TOPICAL	CREAM	2.78 %w/w
TALLOW GLYCERIDES	TOPICAL	EMULSION	2.55 %w/w
DIACETYLATED MONOGLYCERIDES	ORAL	CAPSULE, DELAYED RELEASE PELLETS	4 mg